Haleon (LON:HLN) Receives “Buy” Rating from Jefferies Financial Group

Haleon (LON:HLN)‘s stock had its “buy” rating reissued by Jefferies Financial Group in a research note issued on Monday,London Stock Exchange reports. They currently have a GBX 450 price target on the stock. Jefferies Financial Group’s price objective suggests a potential upside of 19.62% from the company’s previous close.

Several other equities research analysts have also recently issued reports on the stock. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Haleon from GBX 340 to GBX 335 and set a “buy” rating on the stock in a report on Thursday, January 22nd. Berenberg Bank increased their price target on Haleon from GBX 510 to GBX 512 and gave the company a “buy” rating in a report on Thursday, March 19th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Haleon has an average rating of “Moderate Buy” and an average price target of GBX 407.

Haleon Stock Performance

LON:HLN traded up GBX 9.30 during mid-day trading on Monday, reaching GBX 376.20. The company’s stock had a trading volume of 20,708,824 shares, compared to its average volume of 35,200,227. The company has a current ratio of 0.92, a quick ratio of 0.93 and a debt-to-equity ratio of 52.26. The stock has a market cap of £33.51 billion, a P/E ratio of 20.34, a PEG ratio of 1.49 and a beta of 0.25. The firm’s fifty day moving average price is GBX 385.76 and its two-hundred day moving average price is GBX 367.44. Haleon has a 12-month low of GBX 325.10 and a 12-month high of GBX 419.50.

Haleon (LON:HLN) last announced its quarterly earnings results on Thursday, February 26th. The company reported GBX 18.60 earnings per share (EPS) for the quarter. Haleon had a net margin of 13.81% and a return on equity of 9.44%. On average, equities analysts forecast that Haleon will post 19.5033282 EPS for the current fiscal year.

Insider Activity

In related news, insider Brian McNamara sold 704,974 shares of the firm’s stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of GBX 368, for a total value of £2,594,304.32. Insiders own 0.02% of the company’s stock.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.